The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the effectiveness of the Pfizer/BioNTech BNT162B2 vaccine against the Delta variant of SARS-CoV-2 among adolescents.
COVID-19 Vaccine Safety harvard.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from harvard.edu Daily Mail and Mail on Sunday newspapers.
Largest Study Makes Shock Findings on COVID-19 Vaccine Safety thenews-chronicle.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenews-chronicle.com Daily Mail and Mail on Sunday newspapers.
The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the safety of the Pfizer/BioNTech BNT162B2 vaccine against COVID-19.
E-Mail
Several weeks following the publication of the large real-world Covid-19 vaccine effectiveness study by the Clalit Research Institute in Collaboration with Harvard University in the
New England Journal of Medicine (NEJM), additional results focusing on vaccine effectiveness in specific sub-populations have now been published.
While the original publication demonstrated the effectiveness of the Pfizer-BioNTech mRNA vaccine in the general population, outstanding questions remained regarding vaccine effectiveness in specific sub-populations of interest, including the elderly, multi-morbid individuals, and individuals with specific prevalent chronic conditions.
The new study also took place in Israel and evaluated data on approximately 1,400,000 Clalit members, with extended follow-up time compared to the previous study, and additional subpopulations. The advanced methodologies employed meticulous individual matching techniques to enable an as-clean-as-possible analysis